XHKG
1358
Market cap164mUSD
Oct 09, Last price
0.91HKD
1D
0.00%
1Q
-15.74%
Jan 2017
-54.95%
IPO
-73.62%
Name
PW Medtech Group Ltd
Chart & performance
P/E
11.69
P/S
1.34
EPS
0.07
Div yield, %
10.66%
Shrs. gr., 5y
-0.76%
Rev. gr., 5y
27.20%
Revenues
824m
+7.10%
Net income
94m
-37.41%
CFO
241m
-24.41%
Dividend
Nov 02, 20260.011 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating within the People's Republic of China, PW Medtech Group Limited is an investment holding company primarily engaged in the medical device industry. The company specializes in the manufacturing and distribution of a diverse portfolio of medical consumables, including various types of infusion sets such as non-PVC, precision filter, and light-resistant models, alongside intravenous cannula products and insulin needles and pens. Beyond its core medical device activities, the group also provides property management services. Established in 1997, the company, previously known as Pyholding Limited, maintains its corporate headquarters in Beijing, China.
Key people
Jie Wang
Chief Financial Officer · since 2012
Yikun Chen
Vice President · since 2014
Wei Hua
Vice President · since 2011
Liwei Jiang
Non-Executive Director · since 2019
Xiaogang Wang
Independent Non-Executive Director · since 2013
Xingdong Zhang
Independent Non-Executive Director · since 2013
Legal address
Grand Pavilion Commercial Centre, Oleander Way, 802 West Bay Road, P.O. Box 32052, Grand Cayman KY1-1208
Cayman Islands
KY
Cayman Islands
KY
Headquarters
Building 1, Courtyard 23, Panlong West Road, Mafang Industrial Park, Pinggu District
Beijing 101204
CN
Beijing 101204
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||